Contrary to these reassuring safety data, a cohort study of people receiving pharmacotherapy for weight management indicated a significantly increased risk for pancreatitis, bowel obstruction and gastroparesis in those treated with GLP-1 agonists (61), including a 5-fold and 9-fold increased likelihood to develop pancreatitis and gastroparesis in semaglutide-treated patients, respectively (61). The gene discussed is GCG; the disease is pancreatitis.